1 Metabolic phenotyping reveals a potential link between elevated faecal amino acids, diet and 2 symptom severity in individuals with severe mental illness

3

4 Authors

5 Jack Jansma ^{1*}, Rogier van Essen ^{1*}, Bartholomeus C.M. Haarmann ², Anastasia
6 Chrysovalantou Chatziioannou ¹, Jenny Borkent ³, Magdalini Ioannou ^{2,3}, Saskia van Hemert ⁴, Iris E.C.
7 Sommer ^{3#}, Sahar El Aidy ^{1#}

8

9 Affiliations

10 ¹ Host-microbe Interactions, Groningen Biomolecular Sciences and Biotechnology Institute (GBB),
11 University of Groningen, Groningen, The Netherlands.

12 ² Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands

13 ³ Department of Biomedical Sciences of Cells & Systems, University Medical Center Groningen,
14 Groningen, The Netherlands

15 ⁴ Winclove Probiotics, Amsterdam, the Netherlands

16

17 * Shared first author

18 # Shared corresponding author

19 Iris E.C. Sommer. Department of Biomedical Sciences of Cells & Systems, University Medical Center
20 Groningen, Groningen, The Netherlands. E: i.e.c.sommer@umcg.nl

21 Sahar El Aidy. Host-microbe Interactions, Groningen Biomolecular Sciences and Biotechnology
22 Institute (GBB), University of Groningen, Nijenborgh 7, 9747 AG Groningen, The Netherlands. P:
23 +31(0)503632201.

24 E: sahar.elaidy@rug.nl

25

26

27 **List of abbreviations**

28 **BD:** Bipolar disorder

29 **BGA:** Brain-gut axis

30 **BMI:** Body mass index

31 **BPRS:** Brief psychiatric rating scale

32 **CRP:** C-reactive protein

33 **DHD-index:** Dutch healthy diet index

34 **ESAM:** Endothelial cell-selective adhesion molecule

35 **GSRS:** Gastrointestinal symptoms rating scale

36 **¹H-NMR:** Proton nuclear magnetic resonance

37 **IgG:** Immunoglobulin G

38 **PANSS:** Positive and negative symptom scale

39 **SSD:** Schizophrenia spectrum disorders

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 Abstract

59 The brain-gut axis is increasingly recognized as an important contributing factor in the onset and
60 progression of severe mental illnesses such as schizophrenia spectrum disorders and bipolar
61 disorder. This study investigates associations between levels of faecal metabolites identified using
62 ¹H-NMR, clinical parameters, and dietary components of forty-two individuals diagnosed in a
63 transdiagnostic approach to have severe mental illness. Faecal levels of the amino acids; alanine,
64 leucine, and valine showed a significant positive correlation with psychiatric symptom severity as
65 well as with dairy intake. Overall, this study proposes a diet-induced link between the brain-gut axis
66 and the severity of psychiatric symptoms, which could be valuable in the design of novel dietary or
67 therapeutic interventions to improve psychiatric symptoms.

68
69 **Keywords:** Proton nuclear magnetic resonance; faecal metabolites; Schizophrenia spectrum disorder;
70 Bipolar disorder; Brain-gut axis, diet.

71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86

87 Introduction

88 While the etiology of schizophrenia spectrum disorders (schizophrenia, schizophreniform disorder or
89 schizoaffective disorder, SSD) and bipolar disorder (BD) is still largely unknown, current hypotheses
90 include genetic, environmental and inflammatory factors (Carvalho et al., 2020; Horrobin et al., 1994;
91 McCutcheon et al., 2020; Müller, 2018) as key contributing factors. Indeed, both disorders have been
92 associated with increased pro-inflammatory status in the blood and brain. Furthermore, deviations of
93 the gut microbiome have been reported in both SSD and BD, highlighting the role of the brain-gut
94 axis (BGA) (Genedi et al., 2019). Importantly, gut-related disorders such as irritable bowel syndrome,
95 are commonly reported in individuals with SSD or BD (Gupta et al., 1997; Lee et al., 2015).
96 Additionally, frequently used medication such as clozapine, olanzapine, haloperidol and lithium have
97 been shown to affect gut motility and microbiota composition (Flowers et al., 2017; Severance et al.,
98 2015; Sublette et al., 2021; Xu et al., 2021), supporting the BGA as a significantly contributing factor
99 in the etiology of these psychiatric disorders. Such findings spiked the interest to better understand
100 the potential role of the gut and its residing microbes, aiming at the development of therapeutic
101 interventions targeting the BGA to ameliorate the severity of psychiatric disorders such as SSD and
102 BD (Ligezka et al., 2020; Lucidi et al., 2021; Mörk et al., 2020).

103 Among several existing hypotheses on the origin of SSD and BD, the membrane hypothesis
104 postulates that SSD is a systemic disease originating from increased membrane dysfunction in both
105 the brain and gut (Horrobin et al., 1994), resulting in increased translocation of metabolites, and
106 toxic compounds from the gut to the bloodstream and eventually reaching the brain (Bischoff et al.,
107 2014). A genome-wide association study identified an association between the endothelial cell-
108 selective adhesion molecule (*ESAM*) gene and SSD (Pouget et al., 2016). *ESAM* is expressed on
109 endothelial cells and is associated with tight junction proteins in the blood-brain barrier and the
110 intestinal barrier (Nasdala et al., 2002; Uhlén et al., 2015). In SSD, altered endothelial barrier function
111 in the brain was associated with an influx of macrophages in the brain, increased pro-inflammatory
112 status (Cai et al., 2018) and decreased memory functioning (Cai et al., 2020). Moreover, both SSD and

BD individuals have been reported to have increased serum zonulin levels as well as soluble CD14 (Barber et al., 2019; Kiliç et al., 2020; Severance et al., 2013; Usta et al., 2021). Such intestinal barrier dysfunction and the subsequent translocation of (harmful) substances has been closely linked to altered gut microbiota composition (Chelakkot et al., 2018), which was also reported in individuals with BD and SSD (Evans et al., 2017; Nguyen et al., 2019).

To investigate whether gut-associated metabolites are linked with clinical variables, including psychiatric and gastrointestinal symptom severity, we employed untargeted metabolomics using proton nuclear magnetic resonance spectroscopy ($^1\text{H-NMR}$) on faecal samples collected from forty-two individuals diagnosed in a transdiagnostic approach to have SSD or BD.

Material and methods

Participants and clinical variables

As part of an ongoing randomized control study (GUTS, trial register number NL6385), forty-two participants (15 SSD and 27 BD) were analyzed in this baseline cross sectional analysis. The study was approved by the ethics committee of the University Medical Center Groningen (UMCG) (METc 2018/614) and all participants provided written consent upon explanation of the study procedures. To be eligible for participation in the GUTS study, patients were required to have a DSM-IV-R or DSM-5 diagnosis of schizophrenia (295.x), schizophreniform disorder (295.4), schizoaffective disorder (295.7), or bipolar disorder (296.x). Clinical variables including age, sex, body mass index (BMI) and medication intake were reported. Symptom severity was evaluated by trained interviewers using the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) and gastrointestinal complaints were evaluated by the self-report questionnaire: the gastrointestinal symptoms rating scale (GSRS) (**Table 1**) (Kulich et al., 2008). The participants were asked to fill in the Dutch healthy diet index (DHD-index), which is used to score participants according to their adherence to the Dutch guidelines for a healthy diet and measures the nutrient density of their diet (**Table 2**) (Looman et al., 2017; van Lee et al., 2012). Additionally, each subject handed in a faecal sample, which was stored at -80 °C until further use.

Lyophilization and metabolite extraction

To enable comparison of dry weight and homogenization, the faecal samples were lyophilized. Samples were transferred to a precooled glass vial. The samples were lyophilized overnight in a Zirbus VaCo 5/II freeze dryer at -80 °C, with a vacuum of 0.10 mbar. For metabolite extraction, 20 mg of lyophilized sample was used. A volume of 600 µL buffer 1 (D₂O, 3 mM NaN₃ and 1 mM TSP, pH 7.4) and 600 µL buffer 2 (200 µL methanol-d₄ and 400 µL chloroform-d) was added to the lyophilized faecal material. The samples were vortexed and incubated for 10 minutes at 4 °C. The samples were then centrifuged for 10 minutes, 1100 g at 4 °C. Afterwards, 600 µL of the aqueous phase was

transferred to an 5 mm NMR tube. Preliminary experiments comparing the ^1H -NMR spectra of the aqueous and organic phase showed improved signal in the aqueous phase compared to the organic phase due to removal of the lipid background as described by Hauser et al. (Hauser et al., 2019).

^1H NMR spectroscopy

All NMR spectra were recorded using a Bruker 600 MHz AVANCE II spectrometer equipped with a 5 mm triple resonance inverse cryoprobe and a z-gradient system. The temperature of the samples was controlled at 25 °C during measurement. Prior to data acquisition, tuning and matching of the probe head followed by shimming and proton pulse calibration were performed automatically for each sample. One-dimensional (1D) ^1H NMR spectra were recorded using the first increment of a NOESY pulse sequence with presaturation ($\gamma B_1 = 50$ Hz) for water suppression during a relaxation delay of 4 s and a mixing time of 10 ms. 64 scans of 65,536 points covering 12,335 Hz were recorded and zero filled to 65,536 complex points prior to Fourier transformation, an exponential window function was applied with a line-broadening factor of 1.0 Hz.

^1H NMR data processing

The spectra were phase and baseline corrected and referenced to the internal standard (TSP; δ 0.0 ppm), using the MestReNova software (v.12.0.0-20080, Mestrelab Research). With the same software, spectral alignment was performed selecting manually areas and applying a linear filling method of the missing values, after the exclusion of the water signal and the surrounding empty area (4.70-5.16 ppm). Spectral binning followed from -0.50 to 9.00 ppm with an equal size binning step of 0.001 ppm. Noise removal was performed by averaging each integrated bin separately, and removing the bins with an average below 0.144. The annotation of the bins, highlighted as significant by the statistical analysis, was performed with the Chenomx Profiler software (Chenomx NMR Suite 8.6 and Chenomx 600 MHz, version 11) and the HMDB database 5.0 (<http://www.hmdb.ca>).

191

192 *Statistical analysis*

193 MetaboAnalyst (version 5.0, <https://www.metaboanalyst.ca/>) was used for multivariate statistical
194 analysis of the ¹H-NMR spectra (Pang et al., 2021). Pearson's correlation analysis combined with the
195 Bonferroni correction method ($\alpha < 0.05$) was performed to correlate the bins with the patient data.
196 For confirmation of the obtained associations between the amino acids and the clinical variables as
197 well as the associations between the amino acids and the DHD-index, Pearson's correlation
198 combined with the Benjamini-Hochberg correction method ($\alpha < 0.05$) was performed. All statistical
199 analysis was performed using the psych and corrplot packages in R software version 4.0.4.

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Results

Faecal amino acids correlate with the severity of psychiatric symptoms

Forty-two participants (15 SSD and 27 BD), diagnosed with either SSD or BD were analyzed in a baseline cross sectional analysis as described in the methods section. To explore the potential differences in the metabolic profiles among the recruited individuals, faecal samples were analyzed using ¹H-NMR. The ¹H-NMR spectral data (**Figure 1A**) were binned and subjected to principal component analysis (PCA). No distinction among the samples obtained from the patients could be observed (**Figure 1B**). Accordingly, the samples were not separated into BD and SSD subgroups in further analysis.

The spectral bins were further processed, and the bins were correlated using Pearson correlation with all the clinical characteristics of the patients (**Table 1**). Among the correlated bins, 76 significantly correlated with the brief psychiatric rating scale (BPRS) (Overall and Gorham, 1962). Using the library of Chenomx profiler software and the online human metabolome database version 5.0, 51/76 significantly correlated bins were assigned to 4 key-metabolites: alanine, aspartate, leucine, and valine. To confirm the positive association between the identified segments and the BPRS, a representative peak in the ¹H-NMR spectrum (**Figure 1C**) for each amino acid was integrated, normalized to trimethylsilylpropanoic acid (TSP), and correlated with the BPRS using Pearson correlation (**Figure 2**). The correlations confirmed the positive association found between alanine ($r = 0.64$, p value = 4.9×10^{-5}), leucine ($r = 0.64$, p value = 4.9×10^{-5}) and valine ($r = 0.61$, $P = 1.4 \times 10^{-4}$) and the BPRS, respectively. No other correlations were observed between the identified three amino acids and any other clinical parameter, implying a possible role of the increased faecal levels of alanine, leucine and valine association with higher psychiatric symptom severity (**Figure 3**).

Next, we observed strong correlations among the levels of the faecal alanine, leucine and valine; valine-leucine ($r = 0.89$, p value = 8.12×10^{-14}); valine-alanine ($r = 0.86$, p value = 6.62×10^{-12}); leucine-

alanine ($r = 0.98$, p value = 1.14×10^{-27}), inferring a potential common source of these amino acids. To this end, the nutrient scores obtained by the Dutch healthy diet index (DHD-index) (van Lee et al., 2012) (Table 2, 3) were correlated using Pearson's correlation, with the faecal amino acid levels. Indeed, positive associations between the total dairy intake without cheese, faecal alanine ($r = 0.64$, p value = 3.9×10^{-4}) and leucine ($r = 0.59$, p value = 1.14×10^{-3}) were observed (Figure 4A). Moreover, the macro- and micronutrients typically present in high levels in dairy products such as calcium, potassium, vitamin B2, vitamin B6 and vitamin B12 (Pereira, 2014) were positively associated with the faecal levels of alanine (calcium: $r = 0.5$, p value = 0.012; potassium: $r = 0.48$, p value = 0.015; vitamin B2: $r = 0.63$, p value = 7.2×10^{-4} ; vitamin B6: $r = 0.63$, p value = 7.2×10^{-4} ; vitamin B12: $r = 0.48$, p value = 0.015) and leucine (calcium: $r = 0.48$, p value = 0.015; potassium: $r = 0.49$, p value = 0.013; vitamin B2: $r = 0.6$, p value = 9.4×10^{-4} ; vitamin B6: $r = 0.6$, p value = 9.4×10^{-4} ; vitamin B12: $r = 0.45$, p value = 0.02). The caloric and protein intake showed a positive association with the faecal amino acids alanine ($r = 0.43$, p value = 0.032; $r = 0.54$, p value = 0.0047) and leucine ($r = 0.44$, p value = 0.029; $r = 0.54$, p value = 0.000047) (Figure 4B). Taken together our data show significant positive associations between the dairy-related amino acids detected in faecal samples of trans-diagnosed individuals and the severity of disease symptoms.

269

270

271

272 Discussion

273 In this study, ¹H-NMR was employed to investigate a potential role of intestinal metabolites in mental
274 illness in a trans-diagnostic approach of forty-two individuals with BD or SSD. PCA analysis confirmed
275 the similarity of pathophysiological processes with regard to faecal metabolites among individuals
276 with BD or SSD, as no separation of the metabolic profile between the two groups was detected
277 (Figure 1B).

278 The positive association reported in this study between the faecal amino acids, alanine, leucine,
279 valine and the psychiatric symptom severity is in agreement with other metabolomics studies
280 performed on serum, urine and cerebrospinal fluid from patients with BD. For example, elevated
281 levels of alanine were reported in BD individuals compared to healthy controls (Sethi et al., 2017a; Xu
282 et al., 2014; Yoshimi et al., 2016). Analogously, higher levels of valine were detected in urine and
283 serum samples of SSD individuals, respectively (Yang et al., 2011).

284 Our findings point to a possible common source, dairy products, of the three amino acids elevated in
285 the faecal samples of the patients. In fact, Severance et al. showed a positive correlation between
286 the negative psychiatric symptoms according to the positive and negative symptom scale (PANSS) in
287 SSD patients and serum levels of immunoglobulin G (IgG) against the α_s and κ subunit of bovine
288 casein, the major protein component in milk (Severance et al., 2010). Interestingly, leucine is the
289 major amino acid in bovine casein (Rafiq et al., 2016). Other studies have found increased levels of
290 serum immunoglobulin A and IgG against gliadin, one of the major components of gluten, in
291 individuals with BD or SSD compared to healthy controls, though the levels did not correlate with
292 psychiatric symptom severity according to the PANSS (Dickerson et al., 2011, 2010). Besides,
293 countries with a high national intake of sugar and dairy products have been reported to have a more

severe 2-year outcome of SSD (Peet, 2004), highlighting a key role of the diet in the severity of mental illnesses.

In addition to the diet being a plausible source of the metabolites we detected; the increased levels of these amino acids may have originated from the metabolization of the dietary components by the gut microbiota. Indeed, Zheng et al. showed an increase of, among others, alanine, leucine, and valine in the serum and faecal samples of mice transplanted with faecal material from SSD individuals. The microbiota-based altered metabolites were further detected in the hippocampus of mice transplanted with SSD faecal material and were accompanied by behavioral changes related to SSD (Zheng et al., 2019), highlighting a significant role of the gut microbiota and their metabolic capacity in the development of SSD.

The potential adverse (indirect) effects of the diet are possibly mediated by an impaired intestinal barrier function. This results in increased translocation of gut- and microbiota related metabolites from the lumen of the gut to the bloodstream and eventually the brain, accompanied by an increased inflammatory response (Bischoff et al., 2014). Recently, Carloni et al. showed that inflammation originating in the gut can induce propagation of the inflammation to the brain via increasing permeability of the blood-brain barrier, which may be responsible for the observed mental symptoms in individuals with inflammatory bowel disease (Carloni et al., 2021). Indeed, abnormal immune responses have been reported both in patients with SSD and BD, of varying disease stages and medication status (Beumer et al., 2012; Horváth and Mirnics, 2014; Muller and J. Schwarz, 2010; Munkholm et al., 2013). In systematic reviews involving thousands of patients, both disorders were robustly associated with increased C-reactive protein (CRP) levels, especially during early-phase acute psychosis (Fond et al., 2018) and during mania (Fernandes et al., 2016). Moreover, both disorders have been reported to be associated with an increased pro-inflammatory gene expression in circulating monocytes (Drexhage et al., 2010) and symptom severity was found to correlate with levels of inflammatory markers (Fan et al., 2010, 2007; Hope et al., 2013). Similarly, a meta-analysis comparing cytokine profiles in patients with SSD, BD, and major depressive disorder demonstrated

manifest alterations in blood cytokine levels most consistent with an inflammatory profile and T-cell activation (Goldsmith et al., 2016). This analysis with high scientific impact concluded that despite between-study heterogeneity, there were remarkable similarities in the patterns that suggest that abnormal immune responses may be, at least partially, responsible for the reported findings. Taken together, our results highlight a potential link between elevated faecal amino acids, diet and symptom severity in individuals with severe mental illness and urges for the need for further investigations into the interplay between diet, brain and gut.

Limitations

The results of this research should be interpreted in light of some limitations. The small sample size including potential medication effect precludes the conclusion of any causation and limits the correlation analysis, as well as the lack of a matched control group. Moreover, although ¹H-NMR spectroscopy-based metabolomics analysis has been shown to be a useful strategy to investigate the pathophysiology of BD and SSD (Sethi et al., 2017b; Tasic et al., 2017), particularly in serum samples, the sensitivity of ¹H-NMR is relatively low. Therefore, metabolites in concentrations below the detection limit are missed, which impacts the outcome of the study. Nonetheless, we consider this pioneer work and encourage more extensive research into the BGA in SSD and BD.

Conclusion

Overall, the present study shows a significant role of the interplay between the diet-brain-gut axis in the severity of mental illness, which helps guide the development of novel dietary, and microbiota-based interventions.

346

347

348

349

350

351 **Author Contributions:** Jack Jansma: Formal analysis, writing-original draft. Rogier van Essen:
352 Conceptualization, methodology, investigation. Bartholomeus C.M. Haarman: Conceptualization,
353 writing-review and editing, funding acquisition. Anastasia Chrysovalantou Chatziioannou:
354 methodology, writing-review and editing. Jenny Borkent: writing-review and editing. Magdalini
355 Ioannou: writing-review and editing. Saskia van Hemert: Conceptualization. Iris E.C. Sommer:
356 Conceptualization, funding acquisition, writing-review and editing. Sahar El Aidy: Conceptualization,
357 writing-review and editing, funding acquisition. All authors have read and agreed to the published
358 version of the manuscript.

359

360 **Institutional Review Board Statement:** The study was conducted according to the guidelines of the
361 Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of
362 University Medical Center Groningen (UMCG) (METc 2018/614; March 19, 2019).

363

364 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the
365 study.

366

367 **Data Availability Statement:** The data presented in this study are available on request from the
368 corresponding author, upon completion of the study.

369

Conflicts of Interest: S. van Hemert is employee in Winlove (Winlove manufactures and markets probiotics). The content of this study was neither influenced nor constrained by this fact. The other authors have no conflicts of interest to declare.

Funding: This research was funded by Stanley Medical Research Institute, grant number 18T-004 and ZonMw, grant number 636320010.

Acknowledgements: We thank Dr. Johan Kemmink and ing. Pieter van der Meulen of the Stratingh institute of chemistry, University of Groningen, The Netherlands for assisting us with the ^1H -NMR measurements.

Figure legends

Figure 1: Representative examples of ^1H -NMR spectra

A) Two ^1H -NMR spectra representative for an individual with BD and a low (red) and an individual with SSD and a high (green) BPRS score. Both spectra are shown separately and overlapping. The area of water (4.70 – 5.16 ppm) was removed. B) The scores plot of principal component analysis (PCA) based on the first two principal components (PCs), which explain 77.0 % of the variance (68.7 % and 8.3 % for PC1 and PC2 respectively). C) Two ^1H -NMR spectra representative for an individual with BD and a low (red) and an individual with SSD and a high (green) BPRS score. The integrated peaks are indicated with black arrows. SSD: schizophrenia spectrum disorder; BD: bipolar disorder.

Figure 2: Schematic overview of the workflow starting with the obtained ^1H -NMR spectra

A schematic overview depicting the workflow performed starting with the binned spectra. For each step, the number of bins removed or retained is indicated. BPRS: brief psychiatric symptom scale; Benj.-Hoch.: Benjamini-Hochberg.

Figure 3: Pearson's correlation of the clinical variables and amino acids

Pearson's r correlation between the relative area under the curve of a representative peak corresponding to the amino acids and clinical variables. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$. GSRS: gastrointestinal rating scale; BPRS: brief psychiatric symptom scale; CRP: C-reactive protein; BMI: body mass index.

Figure 4: Pearson's correlation of the amino acids and the BPRS with the Dutch healthy diet index.

A) Pearson's correlations between the daily intake of participants per category according to the Dutch healthy diet (DHD) index (van Lee et al., 2012). B) Pearson's correlations between the daily macro and micro nutrient intake of participants according to the DHD index. Only significant correlations are colored ($P < 0.05$). The correlation coefficient is given for each significant association.

Tables and Figures

Tables:

Table 1: Clinical variables of the cohort

The clinical variables, blood parameters and medication intake of the cohort. The median of each variable is given with the minimal and maximal value in brackets. SSD: schizophrenia spectrum disorder; BD: bipolar disorder; BMI: body mass index; BPRS: brief psychiatric rating scale; GSRS: gastrointestinal symptoms rating scale; Syst: systolic; Dias: diastolic; CRP: C-reactive protein

Clinical variables	Number of participants	Median (Min – Max)
Participants	42	
SSD	16	
BD	26	
Male	16	
Age	42	51 (22-64)
Height (cm)	39	173.5 (160.0-194.0)
Weight (cm)	39	75.0 (57.5-120.5)
BMI (kg/m ²)	39	24.5 (18.3-35.3)

Waist size (cm)	28	94 (71-123)
BPRS	42	34 (24-62)
GSRS	41	36 (18-68)
Heartrate (/min)	38	66 (45-100)
Syst. blood pressure (mmHg)	39	129 (104-175)
Dias. blood pressure (mmHg)	39	82 (69-110)

Blood parameters

Albumin (g/L)	42	46 (39-49)
Glucose (mmol/L)	42	5.4 (4.0-13.0)
CRP (mg/L)	42	0.9 (0.3-23.0)
HDL-cholesterol (mmol/L)	42	1.3 (0.7-3.0)
Triglyceride (mmol/L)	42	1.2 (0.3-4.0)

Medication

Haloperidol	1
Arpriprazol	3
Clozapine	1
Quetiapine	1
Risperidon	2
Lithium	9
Valproate	3
Quetiapine & lithium	3
Haloperidol & lamotrigine	1
Olanzapine & valproate	1
Olanzapine & lithium	2
Aripriprazol & lithium	1
Clozapine & topiramate	1
Haloperidol & lithium	1
Antidepressants	8

414

415

416

417
418
419
420
421
422
423
424
425
426
427
428
429
430

Table 2: Daily intake of participants per category and the macro- and micronutrient density according to the Dutch healthy diet index

The daily intake of the participants per category and the macro- and micronutrient density according to the Dutch healthy diet index (van Lee et al., 2012). The median of each category is given with the minimal and maximal value in brackets. DHD: Dutch healthy diet; Sweet. Bever.: Sweetened beverages; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; PUFA-C3: N3-fatty acids; PUFA-C6: N6-fatty acids; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid.

DHD index product categories	Number of participants	Median (Min – Max)
Vegetables (g/day)	41	125.8 (5.4-374.4)
Fruit (g/day)	41	138.7 (8.4-305.9)
Whole grain products (g/day)	41	139.5 (0-312.6)
Refined grain products (g/day)	41	22.6 (0-176.7)
Legumes (g/day)	40	8.7 (-0-69.7)
Nuts (g/day)	40	11.6 (0-81.2)
Dairy without cheese (g/day)	41	133.2 (0-1486.6)
Fish (g/day)	41	7.8 (0-19.2)
Tea (g/day)	39	150.0 (0-1338.0)
Red meat (g/day)	40	9.1 (0-101.5)
Processed meat (g/day)	41	8.3 (0-98.3)
Sweet. Bever. And fruit juice (g/day)	41	22.1 (0-602.9)
Soft fats (g/day)	41	13.0 (0-39.5)

Hard fats (g/day)	41	0 (0-39.5)
Cheese (g/day)	41	13.3 (0-40.0)
<i>DHD-index nutrient scores</i>		
Energy (kJ/day)	41	6197.16 (3051.52 -12636.45)
Protein (g/day)	41	51.64 (19.15-141.31)
Vegetable protein (g/day)	41	27.51 (10.92-53.65)
Total fat (g/day)	41	64.07 (24.74-107.66)
Saturated fat (g/day)	41	24.54 (11.89-45.62)
MUFA (g/day)	41	21.34 (7.72-41.45)
PUFA (g/day)	41	11.01 (3.08-23.82)
Transfat (g/day)	41	1.14 (0.40-2.38)
PUFA-C3 (g/day)	41	1.42 (0.40-2.76)
PUFA-C6 (g/day)	41	9.29 (2.43-20.45)
Alpha-linolenic acid (g/day)	41	1.20 (0.39-2.48)
EPA (g/day)	41	0.06 (0-15)
DHA (g/day)	41	0.09 (0-0.22)
Cholesterol (g/day)	41	114.77 (41.01-255.11)
Carbohydrates (g/day)	41	162.84 (-93.51-369.23)
Monosaccharides (g/day)	41	59.45 (33.82-209.92)
Polysaccharides (g/day)	41	95.73 (38.68-209.92)
Fiber (g/day)	41	19.61 (6.76-35.73)
Water (g/day)	41	1584.99 (716.56-3146.15)
Alcohol (g/day)	41	3.13 (0-37.55)
Calcium (mg/day)	41	601.63 (214.14-2175.02)
Total iron (mg/day)	41	8.82 (3.46-14.76)
Heme iron (mg/day)	41	0.37 (0.02-1.94)
Non-heme iron (mg/day)	41	8.42 (3.38-13.71)
Sodium (mg/day)	41	1550.17 (716.56-3146.15)
Potassium (mg/day)	41	2460.72 (1032.51-5778.82)
Magnesium (mg/day)	41	316.83 (149.82-568.42)
Zinc (mg/day)	41	7.29 (3.11-15.55)

Selenium (mg/day)	41	35.38 (9.74-72.12)
Copper (mg/day)	41	1.18 (0.54-2.21)
Vitamin B1 (mg/day)	41	0.81 (0.37-1.96)
Vitamin B2 (mg/day)	41	0.81 (0.32-3.87)
Vitamin B6 (mg/day)	41	1.22 (0.44-3.88)
Vitamin B12 (µg/day)	41	2.32 (0.22-7.75)
Vitamin D (µg/day)	41	2.00 (0.28-6.50)
Vitamin E (mg/day)	41	8.31 (4.01-18.38)
Vitamin C (mg/day)	41	70.53 (15.96-190.76)
Retinol (µg/day)	41	317.30 (117.77-824.17)
Folic acid equivalents (µg/day)	41	196.81 (93.28-512.60)
Folic acid (µg/day)	41	189.38 (93.29-416.75)

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

Figures

Figure 1: Representative examples of ¹H-NMR spectra

A) Two ¹H-NMR spectra representative for an individual with BD and a low (red) and an individual with SSD and a high (green) BPRS score. Both spectra are shown separately and overlapping. The area of water (4.70 – 5.16 ppm) was removed. B) The scores plot of principal component analysis (PCA) based on the first two principal components (PCs), which explain 77.0 % of the variance (68.7 % and 8.3 % for PC1 and PC2 respectively). C) Two ¹H-NMR spectra representative for an individual with BD and a low (red) and an individual with SSD and a high (green) BPRS score. The integrated peaks are indicated with black arrows. SSD: schizophrenia spectrum disorder; BD: bipolar disorder.

Figure 2: Schematic overview of the workflow starting with the obtained ¹H-NMR spectra

A schematic overview depicting the workflow performed starting with the binned spectra. For each step, the number of bins removed or retained is indicated. BPRS: brief psychiatric symptom scale; Benj.-Hoch.: Benjamini-Hochberg.

Figure 3: Pearson's correlation of the clinical variables and amino acids

Pearson's r correlation between the relative area under the curve of a representative peak corresponding to the amino acids and clinical variables. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$. GSRS: gastrointestinal rating scale; BPRS: brief psychiatric symptom scale; CRP: C-reactive protein; BMI: body mass index.

Figure 4: Pearson's correlation of the amino acids and the BPRS with the Dutch healthy diet index.

A) Pearson's correlations between the daily intake of participants per category according to the Dutch healthy diet (DHD) index (van Lee et al., 2012). B) Pearson's correlations between the daily

macro and micro nutrient intake of participants according to the DHD index. Only significant correlations are colored ($P < 0.05$). The correlation coefficient is given for each significant association.

References

- Barber, G.S., Sturgeon, C., Fasano, A., Cascella, N.G., Eaton, W.W., McMahon, R.P., Kelly, D.L., 2019. Elevated zonulin, a measure of tight-junction permeability, may be implicated in schizophrenia. Schizophrenia Research. <https://doi.org/10.1016/j.schres.2019.07.006>
- Beumer, W., Gibney, S.M., Drexhage, R.C., Pont-Lezica, L., Doorduyn, J., Klein, H.C., Steiner, J., Connor, T.J., Harkin, A., Versnel, M.A., Drexhage, H.A., 2012. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology 92, 959–975. <https://doi.org/10.1189/JLB.0212100>
- Bischoff, S.C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.D., Serino, M., Tilg, H., Watson, A., Wells, J.M., 2014. Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterology. <https://doi.org/10.1186/s12876-014-0189-7>
- Cai, H.Q., Catts, V.S., Webster, M.J., Galletly, C., Liu, D., O'Donnell, M., Weickert, T.W., Weickert, C.S., 2018. Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. Molecular Psychiatry 25:4 25, 761–775. <https://doi.org/10.1038/s41380-018-0235-x>
- Cai, H.Q., Weickert, T.W., Catts, V.S., Balzan, R., Galletly, C., Liu, D., O'Donnell, M., Shannon Weickert, C., 2020. Altered levels of immune cell adhesion molecules are associated with memory impairment in schizophrenia and healthy controls. Brain, Behavior, and Immunity 89, 200–208. <https://doi.org/10.1016/J.BBI.2020.06.017>
- Carloni, S., Bertocchi, A., Mancinelli, S., Bellini, M., Erreni, M., Borreca, A., Braga, D., Giugliano, S., Mozzarelli, A.M., Manganaro, D., Perez, D.F., Colombo, F., Sabatino, A. di, Pasini, D., Penna, G., Matteoli, M., Lodato, S., Rescigno, M., 2021. Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science 374, 439–448. <https://doi.org/10.1126/SCIENCE.ABC6108>
- Carvalho, A.F., Firth, J., Vieta, E., 2020. Bipolar Disorder. <https://doi.org/10.1056/NEJMra1906193> 383, 58–66. <https://doi.org/10.1056/NEJMRA1906193>
- Chelakkot, C., Ghim, J., Ryu, S.H., 2018. Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental & Molecular Medicine 2018 50:8 50, 1–9. <https://doi.org/10.1038/s12276-018-0126-x>

547 Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Alaedini, A., Yolken, R., 2011.
548 Markers of gluten sensitivity and celiac disease in bipolar disorder. *Bipolar Disorders* 13, 52–58.
549 <https://doi.org/10.1111/J.1399-5618.2011.00894.X>

550 Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Leister, F., Yang, S., Krivogorsky, B.,
551 Alaedini, A., Yolken, R., 2010. Markers of Gluten Sensitivity and Celiac Disease in Recent-Onset
552 Psychosis and Multi-Episode Schizophrenia. *Biological Psychiatry* 68, 100–104.
553 <https://doi.org/10.1016/J.BIOPSYCH.2010.03.021>

554 Drexhage, R., Knijff, E., Padmos, R., van der Heul-Nieuwenhuijsen, L., Beumer, W., Versnel, M., 2010.
555 The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia
556 and bipolar disorder. *Expert Review of Neurotherapeutics* 10, 59–76.
557 <https://doi.org/10.1586/ERN.09.144>

558 Evans, S.J., Bassis, C.M., Hein, R., Assari, S., Flowers, S.A., Kelly, M.B., Young, V.B., Ellingrod, V.E.,
559 McInnis, M.G., 2017. The gut microbiome composition associates with bipolar disorder and
560 illness severity. *Journal of Psychiatric Research* 87, 23–29.
561 <https://doi.org/10.1016/J.JPSYCHIRES.2016.12.007>

562 Fan, X., Liu, E.Y., Freudenreich, O., Park, J.H., Liu, D., Wang, J., Yi, Z., Goff, D., Henderson, D.C., 2010.
563 Higher white blood cell counts are associated with an increased risk for metabolic syndrome
564 and more severe psychopathology in non-diabetic patients with schizophrenia. *Schizophrenia*
565 *Research* 118, 211–217. <https://doi.org/10.1016/J.SCHRES.2010.02.1028>

566 Fan, X., Pristach, C., Liu, E.Y., Freudenreich, O., Henderson, D.C., Goff, D.C., 2007. Elevated serum
567 levels of C-reactive protein are associated with more severe psychopathology in a subgroup of
568 patients with schizophrenia. *Psychiatry Research* 149, 267–271.
569 <https://doi.org/10.1016/J.PSYCHRES.2006.07.011>

570 Fernandes, B.S., Steiner, J., Molendijk, M.L., Dodd, S., Nardin, P., Gonçalves, C.-A., Jacka, F., Köhler,
571 C.A., Karmakar, C., Carvalho, A.F., Berk, M., 2016. C-reactive protein concentrations across the
572 mood spectrum in bipolar disorder: a systematic review and meta-analysis. *The lancet.*
573 *Psychiatry* 3, 1147–1156. [https://doi.org/10.1016/S2215-0366\(16\)30370-4](https://doi.org/10.1016/S2215-0366(16)30370-4)

574 Flowers, S.A., Evans, S.J., Ward, K.M., McInnis, M.G., Ellingrod, V.L., 2017. Interaction Between
575 Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. *Pharmacotherapy:*
576 *The Journal of Human Pharmacology and Drug Therapy* 37, 261–267.
577 <https://doi.org/10.1002/PHAR.1890>

578 Fond, G., Lançon, C., Auquier, P., Boyer, L., 2018. C-reactive protein as a peripheral biomarker in
579 schizophrenia. An updated systematic review. *Frontiers in Psychiatry* 9, 1–12.
580 <https://doi.org/10.3389/fpsy.2018.00392>

581 Genedi, M., Janmaat, I.E., Haarman, B.C.M., Sommer, I.E.C., 2019. Dysregulation of the gut-brain axis
582 in schizophrenia and bipolar disorder: Probiotic supplementation as a supportive treatment in
583 psychiatric disorders. *Current Opinion in Psychiatry* 32, 185–195.
584 <https://doi.org/10.1097/YCO.0000000000000499>

585 Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood cytokine network
586 alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and
587 depression. *Molecular psychiatry* 21, 1696–1709. <https://doi.org/10.1038/mp.2016.3>

588 Gupta, S., Masand, P.S., Kaplan, D., Bhandary, A., Hendricks, S., 1997. The relationship between
589 schizophrenia and irritable bowel syndrome (IBS). *Schizophrenia Research* 23, 265–268.
590 [https://doi.org/10.1016/S0920-9964\(96\)00099-0](https://doi.org/10.1016/S0920-9964(96)00099-0)

591 Hauser, A., Eisenmann, P., Muhle-Goll, C., Luy, B., Dötsch, A., Graf, D., Tzvetkova, P., 2019. Efficient
592 Extraction from Mice Feces for NMR Metabolomics Measurements with Special Emphasis on
593 SCFAs. *Metabolites* 9. <https://doi.org/10.3390/METABO9030055>

594 Hope, S., Ueland, T., Steen, N.E., Dieset, I., Lorentzen, S., Berg, A.O., Agartz, I., Aukrust, P.,
595 Andreassen, O.A., 2013. Interleukin 1 receptor antagonist and soluble tumor necrosis factor
596 receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and
597 bipolar disorder. *Schizophrenia Research* 145, 36–42.
598 <https://doi.org/10.1016/J.SCHRES.2012.12.023>

599 Horrobin, D.F., Glen, A.I.M., Vaddadi, K., 1994. The membrane hypothesis of schizophrenia.
600 *Schizophrenia Research* 13, 195–207. [https://doi.org/10.1016/0920-9964\(94\)90043-4](https://doi.org/10.1016/0920-9964(94)90043-4)

601 Horváth, S., Mirnics, K., 2014. Immune System Disturbances in Schizophrenia. *Biological Psychiatry*
602 75, 316–323. <https://doi.org/10.1016/J.BIOPSYCH.2013.06.010>

603 Kılıç, F., Işık, Ü., Demirdaş, A., Doğuç, D.K., Bozkurt, M., 2020. Serum zonulin and claudin-5 levels in
604 patients with bipolar disorder. *Journal of Affective Disorders* 266, 37–42.
605 <https://doi.org/10.1016/j.jad.2020.01.117>

606 Kulich, K.R., Madisch, A., Pacini, F., Piqué, J.M., Regula, J., van Rensburg, C.J., Újszászy, L., Carlsson, J.,
607 Halling, K., Wiklund, I.K., 2008. Reliability and validity of the Gastrointestinal Symptom Rating
608 Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A
609 six-country study. *Health and Quality of Life Outcomes* 6, 1–12. [https://doi.org/10.1186/1477-](https://doi.org/10.1186/1477-7525-6-12)
610 7525-6-12

611 Lee, Y.-T., Hu, L.-Y., Shen, C.-C., Huang, M.-W., Tsai, S.-J., Yang, A.C., Hu, C.-K., Perng, C.-L., Huang, Y.-
612 S., Hung, J.-H., 2015. Risk of Psychiatric Disorders following Irritable Bowel Syndrome: A
613 Nationwide Population-Based Cohort Study. *PLOS ONE* 10, e0133283.
614 <https://doi.org/10.1371/JOURNAL.PONE.0133283>

615 Ligezka, A.N., Sonmez, A.I., Corral-Frias, M.P., Golebiowski, R., Lynch, B., Croarkin, P.E., Romanowicz,
616 M., 2020. A systematic review of microbiome changes and impact of probiotic supplementation
617 in children and adolescents with neuropsychiatric disorders. *Progress in Neuro-*
618 *Psychopharmacology and Biological Psychiatry*. <https://doi.org/10.1016/j.pnpbp.2020.110187>

619 Looman, M., Feskens, E.J.M., de Rijk, M., Meijboom, S., Biesbroek, S., Temme, E.H.M., de Vries, J.,
620 Geelen, A., 2017. Development and evaluation of the Dutch Healthy Diet index 2015. *Public*
621 *Health Nutrition* 20, 2289–2299. <https://doi.org/10.1017/S136898001700091X>

622 Lucidi, L., Pettorruso, M., Vellante, F., di Carlo, F., Ceci, F., Santovito, M.C., di Muzio, I., Fornaro, M.,
623 Ventriglio, A., Tomasetti, C., Valchera, A., Gentile, A., Kim, Y.K., Martinotti, G., Fraticelli, S., di
624 Giannantonio, M., de Berardis, D., 2021. Gut microbiota and bipolar disorder: An overview on a
625 novel biomarker for diagnosis and treatment. *International Journal of Molecular Sciences*.
626 <https://doi.org/10.3390/ijms22073723>

627 McCutcheon, R.A., Marques, T.R., Howes, O.D., 2020. Schizophrenia—An Overview. *JAMA Psychiatry*
628 77, 201–210. <https://doi.org/10.1001/JAMAPSYCHIATRY.2019.3360>

629 Mörk, S., Wagner-Skacel, J., Lahousen, T., Lackner, S., Holasek, S.J., Bengesser, S.A., Painold, A., Holl,
630 A.K., Reininghaus, E., 2020. The role of nutrition and the gut-brain axis in psychiatry: A review of
631 the literature. *Neuropsychobiology*. <https://doi.org/10.1159/000492834>

632 Müller, N., 2018. Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic
633 Considerations. *Schizophrenia Bulletin* 44, 973–982. <https://doi.org/10.1093/SCHBUL/SBY024>

634 Muller, N., J. Schwarz, M., 2010. The Role of Immune System in Schizophrenia. *Current Immunology*
635 *Reviews* 6, 213–220. <https://doi.org/10.2174/157339510791823673>

636 Munkholm, K., Braüner, J.V., Kessing, L.V., Vinberg, M., 2013. Cytokines in bipolar disorder vs. healthy
637 control subjects: A systematic review and meta-analysis. *Journal of Psychiatric Research* 47,
638 1119–1133. <https://doi.org/10.1016/J.JPSYCHIRES.2013.05.018>

639 Nasdala, I., Wolburg-Buchholz, K., Wolburg, H., Kuhn, A., Ebnet, K., Brachtendorf, G., Samulowitz, U.,
640 Kuster, B., Engelhardt, B., Vestweber, D., Butz, S., 2002. A Transmembrane Tight Junction
641 Protein Selectively Expressed on Endothelial Cells and Platelets. *Journal of Biological Chemistry*
642 277, 16294–16303. <https://doi.org/10.1074/JBC.M111999200>

643 Nguyen, T.T., Kosciölek, T., Maldonado, Y., Daly, R.E., Martin, A.S., McDonald, D., Knight, R., Jeste, D.
644 v., 2019. Differences in gut microbiome composition between persons with chronic
645 schizophrenia and healthy comparison subjects. *Schizophrenia Research* 204, 23–29.
646 <https://doi.org/10.1016/J.SCHRES.2018.09.014>

647 Overall, J.E., Gorham, D.R., 1962. THE BRIEF PSYCHIATRIC RATING SCALE1, Psychological Reports. @
648 Southern Universiites Press.

649 Pang, Z., Chong, J., Zhou, G., de Lima Morais, D.A., Chang, L., Barrette, M., Gauthier, C., Jacques, P.-É.,
650 Li, S., Xia, J., 2021. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional
651 insights. *Nucleic Acids Research* 49, W388–W396. <https://doi.org/10.1093/NAR/GKAB382>

652 Peet, M., 2004. International variations in the outcome of schizophrenia and the prevalence of
653 depression in relation to national dietary practices: An ecological analysis. *The British Journal of*
654 *Psychiatry* 184, 404–408. <https://doi.org/10.1192/BJP.184.5.404>

655 Pereira, P.C., 2014. Milk nutritional composition and its role in human health. *Nutrition* 30, 619–627.
656 <https://doi.org/10.1016/J.NUT.2013.10.011>

657 Pouget, J.G., Gonçalves, V.F., Consortium, S.W.G. of the P.G., Spain, S.L., Finucane, H.K.,
658 Raychaudhuri, S., Kennedy, J.L., Knight, J., 2016. Genome-Wide Association Studies Suggest
659 Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases.
660 *Schizophrenia Bulletin* 42, 1176–1184. <https://doi.org/10.1093/SCHBUL/SBW059>

661 Rafiq, S., Huma, N., Pasha, I., Sameen, A., Mukhtar, O., Khan, M.I., 2016. Chemical Composition,
662 Nitrogen Fractions and Amino Acids Profile of Milk from Different Animal Species. *Asian-*
663 *Australasian Journal of Animal Sciences* 29, 1022. <https://doi.org/10.5713/AJAS.15.0452>

664 Sethi, S., Pedrini, M., Rizzo, L.B., Zeni-Graiff, M., Mas, C.D., Cassinelli, A.C., Noto, M.N., Asevedo, E.,
665 Cordeiro, Q., Pontes, J.G.M., Brasil, A.J.M., Lacerda, A., Hayashi, M.A.F., Poppi, R., Tasic, L.,
666 Brietzke, E., 2017a. 1H-NMR, 1H-NMR T2-edited, and 2D-NMR in bipolar disorder metabolic
667 profiling. *International Journal of Bipolar Disorders* 2017 5:1 5, 1–9.
668 <https://doi.org/10.1186/S40345-017-0088-2>

669 Sethi, S., Pedrini, M., Rizzo, L.B., Zeni-Graiff, M., Mas, C.D., Cassinelli, A.C., Noto, M.N., Asevedo, E.,
670 Cordeiro, Q., Pontes, J.G.M., Brasil, A.J.M., Lacerda, A., Hayashi, M.A.F., Poppi, R., Tasic, L.,
671 Brietzke, E., 2017b. 1H-NMR, 1H-NMR T2-edited, and 2D-NMR in bipolar disorder metabolic
672 profiling. *International Journal of Bipolar Disorders* 5:1 5, 1–9.
673 <https://doi.org/10.1186/S40345-017-0088-2>

674 Severance, E.G., Dickerson, F.B., Halling, M., Krivogorsky, B., Haile, L., Yang, S., Stallings, C.R., Origoni,
675 A.E., Bossis, I., Xiao, J., Dupont, D., Haasnoot, W., Yolken, R.H., 2010. Subunit and whole
676 molecule specificity of the anti-bovine casein immune response in recent onset psychosis and
677 schizophrenia. *Schizophrenia Research* 118, 240–247.
678 <https://doi.org/10.1016/J.SCHRES.2009.12.030>

679 Severance, E.G., Gressitt, K.L., Stallings, C.R., Origoni, A.E., Khushalani, S., Leweke, F.M., Dickerson,
680 F.B., Yolken, R.H., 2013. Discordant patterns of bacterial translocation markers and implications
681 for innate immune imbalances in schizophrenia. *Schizophrenia Research* 148, 130–137.
682 <https://doi.org/10.1016/J.SCHRES.2013.05.018>

683 Severance, E.G., Prandovszky, E., Castiglione, J., Yolken, R.H., 2015. Gastroenterology Issues in
684 Schizophrenia: Why the Gut Matters. *Current Psychiatry Reports* 2015 17:5 17, 1–10.
685 <https://doi.org/10.1007/S11920-015-0574-0>

686 Sublette, M.E., Cheung, S., Lieberman, E., Hu, S., Mann, J.J., Uhlemann, A.-C., Miller, J.M., 2021.
687 Bipolar disorder and the gut microbiome: A systematic review. *Bipolar Disorders* 23, 544–564.
688 <https://doi.org/10.1111/BDI.13049>

689 Tasic, L., Pontes, J.G.M., Carvalho, M.S., Cruz, G., Dal Mas, C., Sethi, S., Pedrini, M., Rizzo, L.B., Zeni-
690 Graiff, M., Asevedo, E., Lacerda, A.L.T., Bressan, R.A., Poppi, R.J., Brietzke, E., Hayashi, M.A.F.,
691 2017. Metabolomics and lipidomics analyses by 1H nuclear magnetic resonance of
692 schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis. *Schizophrenia*
693 *Research* 185, 182–189. <https://doi.org/10.1016/J.SCHRES.2016.12.024>

694 Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å.,
695 Kampf, C., Sjöstedt, E., Asplund, A., Olsson, I., Edlund, K., Lundberg, E., Navani, S., Szgyarto,
696 C.A.-K., Odeberg, J., Djureinovic, D., Takanen, J.O., Hober, S., Alm, T., Edqvist, P.-H., Berling, H.,
697 Tegel, H., Mulder, J., Rockberg, J., Nilsson, P., Schwenk, J.M., Hamsten, M., Feilitzén, K. von,
698 Forsberg, M., Persson, L., Johansson, F., Zwahlen, M., Heijne, G. von, Nielsen, J., Pontén, F.,
699 2015. Tissue-based map of the human proteome. *Science* 347.
700 <https://doi.org/10.1126/SCIENCE.1260419>

701 Usta, A., Kılıç, F., Demirdaş, A., Işık, Ü., Doğuç, D.K., Bozkurt, M., 2021. Serum zonulin and claudin-5
702 levels in patients with schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*
703 271, 767–773. <https://doi.org/10.1007/s00406-020-01152-9>

704 van Lee, L., Geelen, A., van Huysduynen, E.J.C.H., de Vries, J.H.M., van't Veer, P., Feskens, E.J.M.,
705 2012. The Dutch Healthy Diet index (DHD-index): an instrument to measure adherence to the
706 Dutch Guidelines for a Healthy Diet. *Nutrition Journal* 2012 11:1 11, 1–9.
707 <https://doi.org/10.1186/1475-2891-11-49>

708 Xu, X.-J., Zheng, P., Ren, G.-P., Liu, M.-L., Mu, J., Guo, J., Cao, D., Liu, Z., Meng, H.-Q., Xie, P., 2014.
709 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar
710 disorder. *Molecular BioSystems* 10, 813–819. <https://doi.org/10.1039/C3MB70614A>

711 Xu, Y., Amdanee, N., Zhang, X., 2021. Antipsychotic-Induced Constipation: A Review of the
712 Pathogenesis, Clinical Diagnosis, and Treatment. *CNS Drugs* 1–10.
713 <https://doi.org/10.1007/S40263-021-00859-0/TABLES/4>

714 Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., Cao, Y., Wang, X., Qiu, Y., Su, M., Zhao, A., Wang,
715 P., Yang, P., Wu, J., Feng, G., He, L., Jia, W., Wan, C., 2011. Potential metabolite markers of
716 schizophrenia. *Molecular Psychiatry* 2013 18:1 18, 67–78.
717 <https://doi.org/10.1038/mp.2011.131>

718 Yoshimi, N., Futamura, T., Bergen, S.E., Iwayama, Y., Ishima, T., Sellgren, C., Ekman, C.J., Jakobsson, J.,
719 Pålsson, E., Kakumoto, K., Ohgi, Y., Yoshikawa, T., Landén, M., Hashimoto, K., 2016.
720 Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar
721 disorder: evidence in support of mitochondrial dysfunction hypothesis. *Molecular Psychiatry*
722 2016 21:11 21, 1504–1510. <https://doi.org/10.1038/mp.2015.217>

723 Zheng, P., Zeng, B., Liu, M., Chen, J., Pan, J., Han, Y., Liu, Y., Cheng, K., Zhou, C., Wang, H., Zhou, X.,
724 Gui, S., Perry, S.W., Wong, M.L., Licinio, J., Wei, H., Xie, P., 2019. The gut microbiome from
725 patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-
726 relevant behaviors in mice. *Science Advances* 5. <https://doi.org/10.1126/SCIADV.AAU8317>

727

728